Get our July/August issue now

available for iOS, Android and web


Shire's Vpriv outshines Genzyme's Cerezyme on bone density

World News | June 29, 2012


Selina McKee

Shire's Vpriv outshines Genzyme's Cerezyme on bone density

Shire has unveiled clinical trial data showing that its Gaucher disease drug Vpriv outperformed its rival, Genzyme's Cerezyme, on a score of bone mineral density (BMD).

The drugmaker said that in a head-to-head trial of the two medicines, only patients treated with its Vpriv (velaglucerase alfa) experienced a statistically significant improvement in lumbar spine BMD after nine months of treatment.

Measuring BMD can help determine the impact of Gaucher disease on a patient’s bone and can therefore help clinicians make decisions on whether treating Gaucher related bone disease is appropriate, so is an important aspect on managing the condition.

The Phase III results show that median lumbar spine Z-scores (mineral matter per square centimeter of bone) at baseline were -1.46 in patients treated with Vpriv and -0.86 in those treated with Cerezyme (imiglucerase), and mean changes from baseline at nine months were 0.33 and 0.06, respectively.

The data show that Vpriv improves Gaucher-related bone disease by inducing a sustained increase in BMD, which is generally less than that of people who don't have the disease, Shire said.

“Many type 1 Gaucher disease patients experience bone abnormalities,” said Professor Ari Zimran, Shaare Zedek Medical Center, Hebrew University and Hadassah Medical School, Jerusalem, Israel. “These study results show that Vpriv is effective in treating selected markers of Gaucher-related bone disease, allowing these patients to achieve an important therapeutic goal quickly,” he noted.

Click here to order a reprint of this news story.

Tags


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

JobSearch


Head-to-Head Video

 

Website Search


Search News Search Magazine